EGFR and head and neck squamous cell carcinoma: Cetuximab, an inhibitory EGFR mAb has received regulatory approval for the treatment of patients with locally or regionally advanced HNSCC in combination with radiation therapy and in combination with platinum/5-FU in patients with recurrent/metastatic HNSCC.